Effect of latanoprost on central corneal thickness in unilateral normal-tension glaucoma
Ja Young You\textsuperscript{1}, Byung Joo Cho\textsuperscript{1}
\textsuperscript{1}Department of Ophthalmology, Konkuk University Medical Center, Seoul - Korea,

**Purpose:** To evaluate the effects of latanoprost on central corneal thickness (CCT) in patients with unilateral normal tension glaucoma (NTG).

**Methods:** Thirty-eight eyes of 38 patients with unilateral NTG who were being followed in our hospital’s glaucoma clinic and were receiving 0.005% latanoprost monotherapy were recruited for the study. The data were collected retrospectively from the patients, who were medicated with latanoprost, at the initial diagnosis of glaucoma. Mean CCT and the CCT reduction from baseline were assessed at initial diagnosis, 3, 6, 9, 12 and 24 months after the initiation of the treatment. An unaffected eye without any ocular medication was also evaluated. All the measurements were performed with a commercially available pachymeter.

**Results:** Mean age was 55.31 ± 11.13 years old. There were no significant differences between the eyes for baseline IOP and CCT. The mean CCT trend to be decreased except at 9 month after treatment in the latanoprost group (affected eye), but only statistically significant after 24 month of treatment. [544.6 ± 38.4 vs. 540.3 ± 37.8 μm (p = 0.013)]. There was no statistically significant change in CCT in the control group (unaffected eye). [545.7 ± 33.7 vs. 545.3 ± 32.1 μm (p = 0.789)].

**Conclusions:** Topical therapy with Latanoprost is associated with CCT reduction over a period of 24 months in patients with unilateral normal tension glaucoma. These data should be taken into consideration in long-standing latanoprost treatment in NTG.